Related Experiment Video
Updated: Mar 12, 2026
16:11
Implantation of the Syncardia Total Artificial Heart
Published on: July 18, 2014
36.2K
Association Between Reduction in Loop Diuretics and Heart Failure Rehospitalization After Transcatheter Aortic Valve
Koki Takegawa1,2, Koshiro Kanaoka1, Yoshitaka Iwanaga1,3
1Department of Medical and Health Information Management, National Cerebral and Cardiovascular Center Osaka Japan.
Circulation Reports
|March 11, 2026
Summary
Reducing loop diuretics (LD) after transcatheter aortic valve replacement (TAVR) significantly lowers heart failure (HF) rehospitalization rates in stable patients. This strategy improves outcomes for post-TAVR HF management.
Area of Science:
- Cardiology
- Heart Failure Management
- Interventional Cardiology
Background:
- Transcatheter aortic valve replacement (TAVR) improves heart failure (HF) but post-procedure HF rehospitalization remains a concern.
- Continued use of loop diuretics (LD) may negatively impact HF patients.
- Investigating LD reduction's effect on HF rehospitalization post-TAVR is crucial.
Purpose of the Study:
- To evaluate the impact of reducing loop diuretics (LD) on heart failure (HF) rehospitalization rates in patients following transcatheter aortic valve replacement (TAVR).
- To analyze the association between changes in LD dosage and HF rehospitalization within two years post-TAVR.
Main Methods:
- Retrospective observational study using Japan's National Database (2014-2021).
- Included 29,358 patients undergoing first-time TAVR without HF worsening within 90 days.
- Categorized patients into No LD, Reduced LD, and Non-Reduced LD groups; used inverse probability of treatment weighting.
Main Results:
- The Reduced LD group showed a significantly lower risk of HF rehospitalization compared to the Non-Reduced LD group (HR 0.46; 95% CI 0.41-0.51; P<0.001).
- Among 29,358 eligible patients, 5,596 were in the Reduced LD group and 4,692 in the Non-reduced LD group.
Conclusions:
- Loop diuretic reduction is associated with decreased heart failure rehospitalization in stable patients after TAVR.
- This finding suggests a potential therapeutic strategy for optimizing post-TAVR HF management.
More Related Videos
Related Concept Videos
01:22Heart Failure Drugs: Diuretics
1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
01:30Heart Failure V: Medical Management
455
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
455
01:25Aortic Regurgitation III: Medical Management
530
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
530
01:22Heart Failure VI: Adjunct Therapies
494
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
494
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
01:15Aortic Regurgitation I: Introduction
1.0K
IntroductionAortic regurgitation is characterized by the backward flow of blood from the aorta into the left ventricle during diastole and arises from the improper closure of the aortic valve. This condition results in left ventricular volume overload and can stem from both acute and chronic etiologies, each contributing uniquely to the disease's progression and symptomatology.Acute and Chronic CausesAcute aortic regurgitation often results from events that suddenly impair the integrity of the...
1.0K